Pharmafile Logo

Communiqué Awards 2016: Excellence in Communication of Survey or Market Research Data

July 13, 2016 | Communiqué Awards, Lucid 

The winning programme – Treating beyond symptoms in IBD: The Steroid Assessment Tool.

Our approach to medical education is really helping to improve patient outcomes and change lives.

Inflammatory bowel disease (IBD) affects more than 250,000 patients in the UK. Treatment strategies have progressed to treating beyond the symptoms of IBD, aiming to reduce mucosal inflammation, sustain remission and prevent bowel damage. 

Steroids have a place in the treatment pathway but do not sustain remission and are associated with significant side effects.The European Crohn’s and Colitis Organisation (ECCO) defines appropriate steroid use and recommends an exit strategy for steroid-dependent patients. However, gastroenterologists are not aware that inappropriate steroid use occurs in their own clinical practice.

Using a simple digital tool, UK experts audited their own practice and were surprised to see high steroid use among their patients. The expert group became advocates for change, motivated to share their data, targeting more than 300 UK HCPs with high steroid use, which comprises approximately 22% of UK IBD clinicians. Awareness of inappropriate steroid use, and the changes driven by the self-realisation of the need to optimise steroids, have the potential to impact the care delivered to over 50,000 UK IBD patients.


This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Cultivating a learner-led culture: agile learning and the growth mindset

In this month’s Smart Thinking blog on PM.Live.com, Michelle Sweet, Learning and Development Consultant at Lucid Group, discusses the needs for a learner-led culture and a growth mindset in the...

Bluedog expands into the US with the appointment of George Pearson as Client Solutions Director

Bluedog, a Lucid Group Company, has elevated and expanded its creative team into the US with the appointment of George Pearson as Client Solutions Director.George is a highly experienced medical...

The inescapable rise of patient-centricity

The April issue of PME questions the meaning of ‘patient-centricity’ and whether we are achieving it.Patient-centricity has become a ubiquitous value within the pharmaceutical industry; however, is pharma delivering on...

Vivid welcomes magical new talent to the team

Vivid Medical Communications, a Lucid Group company, is delighted to announce two magical additions to the team.Deborah Blain joins Vivid as an Account Manager. With over 10 years’ experience in...

Easter Magic for Lucid Group

Lucid’s Futures Executives were set the challenge of planning a magical Easter surprise across its seven offices. After an egg-citing (sorry!) brainstorm the grads chose three activities.-    Egg-cellent Easter egg hunt-    You’re...

Lucid Group announces the appointment of new CFO

Lucid Group continues to build its infrastructure in line with its ambitious growth plans by appointing Michael Joyce as Chief Financial Officer (CFO).Michael has considerable experience as a CFO and...

Lucid Group Launch a Pioneering Leadership Programme for its Business Leaders

Great companies start with great leaders. However effective leadership requires skill, emotional intelligence, and most importantly, on-going self-improvement.With this in mind, Lucid Group has launched a new leadership programme for...

Leading Edge, a Lucid Group company, strengthens its senior client services team

Leading Edge, a Lucid Group company, is delighted to announce the appointment of its new Lead Client Partnership Director, Frances O’Connor.Frances is an experienced strategic healthcare communicator with expertise in...

From Cowgirl to Medical Writer – How did that happen?

Amy Jackson, Editorial Director, Lucid Group discusses her unlikely path into Medical Communications.

Measures for measures

Why pharma’s marketing metrics must close the loop